Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience.

Mol Oncol · 2022 · PMC9251876 · PMID 35238467

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Subsequently, patients who received matched therapies showed a trend towards a higher rate of clinical benefit (41% [13/32]) when compared to patients who received unmatched therapies (18% [3/17]) (odds ratio [OR], 0.21; 95% CI, 0.04–1.06; P = 0.058; multivariate analysis; Table 3 and Fig. 4 ). 4.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.